Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.

What Was Tested

Researchers studied Insulin Lispro and Insulin in this randomized controlled trial publication.

Mealtime insulin is commonly added to manage hyperglycemia in type 2 diabetes when basal insulin is insufficient.

Who Took Part

The study group was 627 patients.

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a randomized, open-label and multicenter study.

Because people in this Insulin Lispro study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Nothing was hidden in this open-label Insulin Lispro study: the patients and staff both knew the treatment.

Running at several centres spread the Insulin Lispro study over different clinics and patient groups.

What Was Measured

Topics PubMed links to this paper include Blood Glucose, Diabetes Mellitus, Type 2, Exenatide, Glucagon-Like Peptide-1 Receptor, Glycated Hemoglobin, Hyperglycemia and Hypoglycemia.

What This Means in Plain Language

The paper is a randomized, open-label and multicenter study of Insulin Lispro and Insulin in 627 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2014 (Diabetes care), a journal based in United States.

More context: the related Insulin Lispro library page, all human trials.